Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2008-04-02 | Reverse | 647:2000 |
MiMedx Group, Inc. develops and distributes patented placental tissue allografts for wound care, surgical recovery, burns, sports medicine, and dental applications primarily in the U.S.
MiMedx's flagship dHACM allograft is a proven, insurance-covered barrier that promotes healing in acute and chronic wounds, exemplifying their focus on advanced wound care.
MiMedx Group announced its third-quarter 2025 financial results, reporting the highest quarterly revenue in the company's history for the second consecutive quarter. Net sales grew 35% year-over-year to $114 million, significantly beating analyst estimates and leading the company to raise its full-year 2025 guidance for both net sales growth and adjusted EBITDA.
MiMedx entered into a strategic collaboration with Vaporox, Inc. to co-promote and co-market their respective wound care offerings. This partnership diversifies MiMedx's portfolio beyond its core placental allografts by adding Vaporox's Vaporous Hyperoxia Therapy (VHT) device, aiming to provide a more comprehensive set of options for treating chronic, hard-to-heal wounds.
MiMedx Group, Inc (NASDAQ: MDXG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among
Overall rating: B
| PEER | PRICE | |
|---|---|---|
 DNTH | $83.95 | COMPARE |
 INVA | $20.92 | COMPARE |
 SNDX | $17.35 | COMPARE |
 RAPP | $30.57 | COMPARE |
 TSHA | $4.38 | COMPARE |
 INBX | $94.51 | COMPARE |
 NKTR | $39.94 | COMPARE |
 SANA | $2.78 | COMPARE |
